Search - tctmd.com

Displaying 141 - 160 of 779

Sort: Relevancy | Date

UK’s NICE Recommends Lower-Risk Thresholds for Statin Therapy

News Daily News

UK’s NICE Recommends Lower-Risk Thresholds for Statin Therapy

Michael O'Riordan

January 20, 2023

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

CT Angiography Is Increasing in England, but Downstream Tests Are Not

News Daily News

CT Angiography Is Increasing in England, but Downstream Tests Are Not

Michael O'Riordan

January 12, 2023

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

News Daily News

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Michael O'Riordan

December 14, 2022

A Simple Nudge Moves the Needle on Statin Prescribing

News Daily News

A Simple Nudge Moves the Needle on Statin Prescribing

Michael O'Riordan

December 02, 2022

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

News Daily News

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

November 21, 2022

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

News Daily News

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Michael O'Riordan

November 17, 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

November 10, 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

New Biomarker-Based Risk Score Performs Well in ACS

News Daily News

New Biomarker-Based Risk Score Performs Well in ACS

Michael O'Riordan

October 25, 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

News Conference News ESC 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

August 29, 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

News Conference News ESC 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Michael O'Riordan

August 29, 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

August 28, 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

News Conference News ESC 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Michael O'Riordan

August 26, 2022

After COVID-19, Unvaccinated at Risk for Long-term CVD Complications

News Daily News

After COVID-19, Unvaccinated at Risk for Long-term CVD Complications

Michael O'Riordan

August 16, 2022

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution

News Daily News

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution

Michael O'Riordan

August 11, 2022

Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy

News Daily News

Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy

July 20, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.